Search Within

Mark Blaine Geyer

Formats
  1. Meeting Abstract (40)
  2. Journal Article (35)
  3. Review (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Adult Leukemia (86)
  2. Center for Hematologic Malignancies (86)
  3. Department of Medicine (86)
  4. Hematologic Malignancies, Division of (86)
  5. Weinberg Fellows (86)
  6. Epidemiology and Biostatistics (30)

More Groups

People
  1. Jae Park (45)
  2. Martin Tallman (20)
  3. Mikhail Roshal (15)
  4. Renier Brentjens (15)
  5. Lindsey Roeker (14)
  6. Andriy Derkach (13)

More People

Years
  1. 2025 (3)
  2. 2024 (8)
  3. 2023 (14)
  4. 2022 (6)
  5. 2021 (8)
  6. 2020 (10)

More Years

Publications
  1. Blood (33)
  2. Leukemia and Lymphoma (8)
  3. Blood Advances (5)
  4. Haematologica (3)
  5. Journal of Clinical Oncology (3)
  6. Cytotherapy (2)

More Publications

Publishers
  1. American Society of Hematology (38)
  2. Taylor & Francis Group (9)
  3. Elsevier Inc. (6)
  4. American Society of Clinical Oncology (4)
  5. Nature Publishing Group (4)
  6. American Association for Cancer Research (3)

More Publishers

Results (86)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • Phase I trial: CD19-targeted CAR T-cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M.; Park, J.; Rivière, I.; Senechal, B.; Hsu, M.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
    Journal Article

    Geyer, M. B.; Brentjens, R. J.
    Cytotherapy (2016)

    Fulltext@MSK | Save
  • CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date
    Journal Article

    Park, J. H.; Geyer, M. B.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • Reduced toxicity conditioning and allogeneic hematopoietic progenitor cell transplantation for recessive dystrophic epidermolysis bullosa
    Journal Article

    Geyer, M. B.; Radhakrishnan, K.; Giller, R.; Umegaki, N.; Harel, S.; Kiuru, M.; Morel, K. D.; LeBoeuf, N.; Kandel, J.; Bruckner, A.; more...
    Journal of Pediatrics (2015)

    Fulltext@MSK | Save